Syncona's Autolus leukemia treatment meets trial endpoint
Autolus Therapeutics Plc
$2.26
09:54 27/12/24
Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) patients has met its primary endpoint at interim analysis.
Equity Investment Instruments
12,150.37
16:29 27/12/24
FTSE 250
20,488.65
16:29 27/12/24
FTSE 350
4,495.62
16:29 27/12/24
FTSE All-Share
4,453.14
17:05 27/12/24
Syncona Limited NPV
103.20p
16:40 27/12/24
Its treatment demonstrated an overall remission rate, the primary endpoint for the trial, of 70% in an interim analysis of 50 patients, the company said on Friday.
Martin Murphy, chief executive of Syncona Investment Management, said: "Today's announcement from Autolus marks an important moment for the company as it progresses its lead programme of obe-cel in adult ALL.”
“The data is consistent with what was previously presented in the ALLCAR19 academic study, underlining the potential of obe-cel as a drug which can provide meaningful impact for patients suffering from ALL whilst also showing a very positive safety profile in a last line setting.”
“We are also encouraged by the expansion and persistence of obe-cel and look forward to future updates on whether this translates into potential best-in-class clinical durability.”
Reporting by Frank Prenesti for Sharecast.com